Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

Jasper Dingemanse, Patricia N. Sidharta, Willis C. Maddrey, Lewis J. Rubin, Hani Mickail

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Introduction: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. Areas covered: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH. Expert opinion: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class. The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose. The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration. The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite. The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments. Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH. Its potential use in other disorders is under investigation.

Original languageEnglish (US)
Pages (from-to)391-405
Number of pages15
JournalExpert Opinion on Drug Safety
Volume13
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Clinical Pharmacology
Pulmonary Hypertension
Safety
Therapeutics
Morbidity
Drug Evaluation
Mortality
Liver
Endothelins
Expert Testimony
Endothelin Receptor Antagonists
macitentan
Drug Interactions
Pharmaceutical Preparations
Edema
Hemoglobins
Pharmacokinetics
Kidney

Keywords

  • Clinical pharmacology
  • Drug safety
  • Endothelin receptor antagonists
  • Macitentan
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. / Dingemanse, Jasper; Sidharta, Patricia N.; Maddrey, Willis C.; Rubin, Lewis J.; Mickail, Hani.

In: Expert Opinion on Drug Safety, Vol. 13, No. 3, 03.2014, p. 391-405.

Research output: Contribution to journalArticle

@article{927fa719378b4ac998efd3310a896e80,
title = "Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension",
abstract = "Introduction: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. Areas covered: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH. Expert opinion: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class. The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose. The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration. The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite. The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments. Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH. Its potential use in other disorders is under investigation.",
keywords = "Clinical pharmacology, Drug safety, Endothelin receptor antagonists, Macitentan, Pulmonary arterial hypertension",
author = "Jasper Dingemanse and Sidharta, {Patricia N.} and Maddrey, {Willis C.} and Rubin, {Lewis J.} and Hani Mickail",
year = "2014",
month = "3",
doi = "10.1517/14740338.2014.859674",
language = "English (US)",
volume = "13",
pages = "391--405",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

AU - Dingemanse, Jasper

AU - Sidharta, Patricia N.

AU - Maddrey, Willis C.

AU - Rubin, Lewis J.

AU - Mickail, Hani

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. Areas covered: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH. Expert opinion: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class. The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose. The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration. The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite. The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments. Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH. Its potential use in other disorders is under investigation.

AB - Introduction: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. Areas covered: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH. Expert opinion: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class. The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose. The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration. The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite. The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments. Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH. Its potential use in other disorders is under investigation.

KW - Clinical pharmacology

KW - Drug safety

KW - Endothelin receptor antagonists

KW - Macitentan

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84896696727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896696727&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.859674

DO - 10.1517/14740338.2014.859674

M3 - Article

C2 - 24261583

AN - SCOPUS:84896696727

VL - 13

SP - 391

EP - 405

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -